GLP-1

Bio News

The European Commission approves the acquisition of Catalent by Novo Holdings and the related acquisition by Novo Nordisk of three manufacturing sites from Novo Holdings

Novo Nordisk still expects the acquisition to be completed towards the end of 2024

2024年12月7日

1190

BD交易新闻

【重磅消息】欧盟委员会无条件批准了Novo Holdings对Catalent的165亿美元收购计划

药时代将持续跟踪报道这一重要交易的进展，欢迎广大朋友们关注药时代，获取最新资讯！

2024年12月7日

8960

Request for Product

NASDAQ-listed companies are looking for obesity drugs with the potential for weight loss and muscle gain

If your company is interested in this opportunity, please contact the DrugTimes BD team as soon as possible!

2024年8月23日

1350

原创作品

GLP-1触发的 “连招”，何止医美？

GLP-1已成当下MNC研发管线的标配。除已有大热产品上市的诺和诺德、礼来外，近期包括罗氏、辉瑞也接连宣布其在研GLP-1产品的好消息。 2024年7月15日，国外媒体ENDPO…

2024年7月17日

6130

Insights

Try again! Pfizer ‘revives’ its oral GLP-1RA

DrugTimes will present more reports. Please stay tuned

2024年7月16日

3280

What is the Current Landscape of Obesity Drug Development in China?

These presentations indicate that the era of domestically developed GLP-1 drugs for weight loss in China is on the horizon, with significant implications for the future of obesity treatment

Insights 2024年7月2日

2040

Bio News

Structure Therapeutics Reports Positive Topline Data from its Phase 2a Obesity Study and Capsule to Tablet PK Study for its Oral Non-Peptide Small Molecule GLP-1 Receptor Agonist GSBR-1290

Structure Therapeutics announced positive 12-week topline obesity data from its Phase 2a study of GSBR-1290, along with positive topline results from its capsule to tablet PK study. Both studies achieved their primary and secondary objectives

2024年6月4日

2800